Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akinori Nagashima is active.

Publication


Featured researches published by Akinori Nagashima.


American Journal of Nephrology | 1995

Cellular immunity in hemodialysis patients: a quantitative analysis of immune cell subsets by flow cytometry

Souzana Sabeva Deenitchina; Takash Ando; Seiya Okuda; Naoko Kinukawa; Hideki Hirakata; Akinori Nagashima; Masatoshi Fujishima

Immune cell subsets, when measured by two-color flow cytometry in a population of 129 hemodialysis patients, showed significant variance from normal values. Lymphopenia, decreased absolute counts, and altered percentage values of immune cells were found. Increased proportions of CD3+, T cell receptor (TCR) alpha beta + cells and CD4+ T lymphocytes were present. An abnormally high percentage of a subset of activated TCR alpha beta + cells (alpha beta + DR+) was also seen in hemodialysis patients. The proportion of B lymphocytes was found to be significantly lower as compared with controls. Relative values for TCR gamma delta+cells, both for activated (gamma delta + DR+) and nonactivated (gamma delta + DR-) subsets, as well as for CD8+ lymphocytes and natural killer cells did not vary from those of normal controls. Also, the CD4+/CD8+ ratio showed no significant change. Analysis of absolute counts of the investigated immune cell populations revealed significantly decreased numbers for the majority of subsets, as a result of the preexisting lymphocytopenia, characteristic of end-stage renal disease. We conclude that profound quantitative alterations of immune cells, including TCR+T cells subsets, exist in hemodialysis patients. These account, at least in part, for the immune dysregulation associated with chronic renal failure.


Life Sciences | 1995

The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients

Hidetoshi Kanai; Akinori Nagashima; Eriko Hirakata; Hideki Hirakata; Seiya Okuda; Satoru Fujimi; Masatoshi Fujishima

Pruritus is a very common complication in chronic hemodialysis (HD) patients, however the exact mechanism for this affliction is still not known. Anti-histaminics usually failed to alleviate uremic pruritus. In others, an anti-allergic drug, which inhibits the release of chemical mediators, such as leukotrienes or histamine from mast cells, was reported to be effective. We evaluated the values of leukotriene B4 and interleukin 6 in HD patients with pruritus and the effect of an anti-allergic drug on these factors. Leukotriene B4, interleukin-6, C3a, C5a, the number of eosinophil and IgE at 0, 15 and 180 minutes after the start of regular HD in 11 HD patients suffering from pruritus and as well as in 11 HD patients without pruritus were examined. These HD patients in both groups showed significantly higher (p < 0.001) values of leukotriene B4 and C3a compared to healthy non-HD subjects. There was no difference in the leukotriene B4, interleukin-6, IgE, C3a and C5a levels between the patients with and without pruritus. Two mg/day of azelastin hydrochloride, an anti-allergic drug was orally given to the pruritus group for 3 weeks. In 5 of 11 patients, the pruritus symptoms disappeared, while in 4 of 11 they improved. Independent of the effect of the drug on pruritus, leukotriene B4 levels significantly decreased compared with those before the administration of this drug in the pruritus group (p < 0.01). Interleukin 6, C3a, C5a and the number of eosinophils demonstrated no significant change. In conclusion, although azelastin hydrochloride was effective in treating pruritus and also suppressed leukotriene B4 levels in hemodialysis patients, the high leukotriene B4 activity itself did not seem to be related to the development of pruritus in these patients.


Peritoneal Dialysis International | 2011

FLUID FLOW STRESS AFFECTS PERITONEAL CELL KINETICS: POSSIBLE PATHOGENESIS OF PERITONEAL FIBROSIS

Shigehisa Aoki; Junichi Makino; Akinori Nagashima; Toshiaki Takezawa; Namie Nomoto; Kazuyoshi Uchihashi; Aki Matsunobu; Toru Sanai; Hajime Sugihara; Shuji Toda

♦ Background: Peritoneal fibrosis is an essential precursor condition to the development of encapsulating peritoneal sclerosis (EPS). This serious complication leads to a high mortality rate in peritoneal dialysis (PD) patients. Although several factors, including highly concentrated glucose in the dialysis solution, are believed to be potent agents for peritoneal fibrosis, the underlying mechanism remains unclear. During PD, the dialysis solution continuously generates fluid flow stress to the peritoneum under peristalsis and body motion. Fluid flow stress has been implicated as playing a critical role in the physiologic responses of many cell types. We therefore hypothesized that fluid flow stress may be involved in the pathogenesis of peritoneal fibrosis leading to EPS. ♦ Methods: To generate fluid flow stress, culture containers were placed on a rotatory shaker in a thermostatic chamber. In this system, the shaker rotated at a speed of 25 rpm with a radius of 1.5 cm. Mesothelial cells were cultured in low-glucose (1000 mg/L) or high-glucose (4500 mg/L) complete medium with and without flow stress. ♦ Results: Fluid flow stress promoted hyperplasia and epithelial-mesenchymal transition (EMT) of mesothelial cells independent of glucose concentration. Fluid flow stress inhibited expression of ERK (extracellular signal-regulated kinase) and p38 MAPK (mitogen-activated protein kinase) in mesothelial cells. Administration of ERK and p38 MAPK inhibitors replicated the stress-induced morphology of mesothelial cells. ♦ Conclusions: The present data indicate that fluid flow stress promotes hyperplasia and EMT of mesothelial cells via the MAPK axis, suggesting that fluid flow stress may be involved in the pathogenesis of peritoneal fibrosis.


Nephron | 1995

Influence of a High Salt Diet on Glomerular Injury and the Preventive Effects of Amiloride in Adriamycin Nephropathy

Akinori Nagashima; Seiya Okuda; Kiyoshi Tamaki; Masatoshi Fujishima

The effects of a high salt diet on glomerular hypertrophy and sclerosis were examined in a focal glomerular sclerosis rat model. Sprague-Dawley rats were injected twice with Adriamycin (ADR, 2.5 mg/kg body weight) and then divided into 3 groups: (1) ADR rats fed a 1% sodium chloride (NaCI) diet (control ADR rats); (2) ADR rats fed an 8% NaC1 diet (ADR-NaC1 group), and (3) ADR rats fed a 10% sodium bicarbonate (NaHCO3) diet (the ADR-NaHCO3 group), and were then observed for 8 weeks. There were no differences in the blood pressure levels between the control ADR and ADR-NaC1 groups. The urinary protein excretion was significantly less in the ADR-NaC1 and ADR-NaHCO3 groups than in the control ADR group. However, a progressive increase in the blood urea nitrogen and serum creatinine associated with extensive glomerular sclerosis and hypertrophy was only observed in the ADR-NaC1 group. An increase in the glomerular diameter preceded the development of glomerulosclerosis in this group. Furthermore, a daily administration of amiloride, a Na+/H+ exchanger inhibitor, to the ADR-NaC1 rats prevented the development of glomerular hypertrophy and sclerosis. These results therefore suggest that the aggravated effect of a high salt diet on glomerular sclerosis may be related to glomerular hypertrophy which is associated with the stimulation of the Na+/H+ exchanger.


Current Therapeutic Research-clinical and Experimental | 1995

Influence of recombinant human erythropoietin and blood transfusions on the composition of lymphocyte populations in hemodialyzed patients

Souzana Sabeva Deenitchina; Takashi Ando; Seiya Okuda; Hidetoshi Kanai; Hideki Hirakata; Akinori Nagashima; Masatoshi Fujishima

Abstract The effects of recombinant human erythropoietin (rHuEpo) treatment and blood transfusions on the composition of lymphocyte populations in chronic renal failure patients undergoing maintenance hemodialysis treatment were examined. Immune cells were investigated in the peripheral blood of 122 hemodialysis patients using two-color flow cytometry analysis. For detection of lymphocyte surface markers, a panel of monoclonal antibodies reactive with the following molecules was used: CD3, CD4, CD8, B cell, CD16, CD56, T-cell receptor αβ heterodimer (TCR αβ), T-cell receptor γδ heterodimer (TCR γδ), and human leukocyte antigen (HLA)-DR. Hemodialysis patients who received rHuEpo treatment were found to have significantly lower percentages of CD3 + lymphocytes compared with untreated patients. rHuEpo administration was shown to affect mainly the subset of T cells bearing TCR αβ (TCR αβ + ). A relative increase in the activated TCR αβ + subsets and a decrease in the nonactivated TCR αβ + subsets were observed in rHuEpo-treated individuals. The significantly elevated TCR αβ + and TCR γδ + subset activation indexes found in patients who received rHuEpo suggested a state of activation of the immune system. A history of blood transfusions was shown to be associated with a higher proportion of cytotoxic (CD8 + ) T cells and a decrease in the helper-suppressor index. Blood transfusions had an effect on the T-cell receptor-bearing lymphocyte populations similar to that of rHuEpo administration. We conclude that both rHuEpo treatment and blood transfusions contribute to altered cellular immunity in end-stage renal disease.


Clinical Nephrology | 1996

Minimal daily variations of plasma and urinary endothelin-1 in healthy subjects.

Hidetoshi Kanai; Hideki Hirakata; Masaru Nakayama; Akinori Nagashima; Masatoshi Fujishima


Kidney International | 1994

Increased expression of Na+/H+ exchanger in the injured renal tissues of focal glomerulosclerosis in rats.

Seiya Okuda; Kiyoshi Tamaki; Takashi Ando; Akinori Nagashima; Masaru Nakayama; Kyoichi Fukuda; Harumichi Higashi; Masatoshi Fujishima


Journal of Epidemiology | 1994

Hepatitis B surface antigen and antibody among chronic hemodialysis patients in Fukuoka, Japan: a high risk for becoming hepatitis B virus carriers

Masakazu Washjo; Noritaka Tokui; Seiya Okuda; Akinori Nagashima; Toru Sanai; Hideki Hirakata; Takesumi Yoshimura; Masatoshi Fujishima


Journal of Japanese Society for Dialysis Therapy | 1991

Clearance of the antiarrhythmic agent cibenzoline succinate during hemodialysis.

Hidetoshi Kanai; Hideki Hirakata; Kiyoshi Tamaki; Masaru Nakayama; Naomichi Higashi; Akinori Nagashima; Seiya Okuda; Masatoshi Fujishima; Kaoru Onoyama; Naohiko Hara; Akihito Yamaguchi; Shinji Yoshida


Clinical Nephrology | 2017

Thyroid function in patients on continuous ambulatory peritoneal dialysis in comparison with chronic kidney disease .

Toru Sanai; Akinori Nagashima; Ken Okamura; Shuichi Rikitake; Makoto Fukuda; Koji Onozawa; Mai Sanematsu; Tsuyoshi Takashima; Motoaki Miyazono; Yuji Ikeda

Collaboration


Dive into the Akinori Nagashima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge